Lyell Immunopharma (LYEL) is the lead sponsor of 3 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 1 Phase 2[2], 2 Phase 1[3].
Trial NCT07188558[5] evaluates rondecabtagene autoleucel in Large B-cell Lymphoma with a target enrollment of 400 participants.
LYEL has 1 Form 4 insider filing recorded at the SEC in the past 30 days[6].